ADARx Pharmaceuticals, Inc. went public at $17.00 a share
It sold 26,250,000 shares on the Nasdaq Global Select Market under the ticker ADRX and raised $446.2 million before costs.
Final prospectus (424B4) filed September 28, 2026
The terms
-
Offered
26,250,000 shares
Checked
Source
“We are offering 26,250,000 shares of our common stock to be sold in this offering.”
A model read this, and code confirmed the quote appears in the filing. -
Price per share
$17.00
Checked
Source
“The initial public offering price is $17.00 per share.”
A model read this, and code confirmed the quote appears in the filing. -
Raised
$446,250,000before fees and costs
Checked
Source and check
Shares × price = 26,250,000 × $17.00 = $446,250,000. They match.
“Initial public offering price | $17.00 | $446,250,000”
A model read this, and code confirmed the quote appears in the filing. -
Bank fee
$31,237,500$1.19 a share, 7.0% of the raise
Checked
Source
“Underwriting discounts and commissions(1) | $1.19 | $31,237,500”
A model read this, and code confirmed the quote appears in the filing. -
Company receives first
$415,012,500before other costs
Checked
Source and check
Raised − bank fee = $446,250,000 − $31,237,500 = $415,012,500. They match.
“Proceeds to ADARx Pharmaceuticals, Inc., before expenses | $15.81 | $415,012,500”
A model read this, and code confirmed the quote appears in the filing. -
Lead banks
J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, LifeSci Capital
From the prospectus
Source
“J.P. Morgan | Morgan Stanley | TD Cowen | UBS Investment Bank | LifeSci Capital”
A model read this, and code confirmed the quote appears in the filing. -
Trades as
ADRX on the Nasdaq Global Select Market
Checked
Source
“Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “ADRX.””
A model read this, and code confirmed the quote appears in the filing. -
Extra for the banks
Up to 3,937,500 sharesan option the banks may use
From the prospectus
Source
“We have granted the underwriters an option for a period of 30 days to purchase up to 3,937,500 additional shares of our common stock.”
A model read this, and code confirmed the quote appears in the filing. - Final prospectus filed September 28, 2026
Not investment advice.Open the filing on SEC.gov
Where the money goes first
The banks take their fee before the company sees the money.
Who owns the company after the IPO
From the prospectus 26,250,000 of 106,801,325 shares outstanding after the offering (24.6%).
Where ADARx Pharmaceuticals, Inc. sits among the last 12 months
Each bubble is one IPO. Bigger and higher means more money raised. The scale grows by ten times at each line.
New to these terms? How to read an IPO.